Key findings
- 4.95 millionestimated deaths were associated with bacterial antimicrobial resistance in 2019, including 1.27 million attributable to resistance
- 48–72 hoursthe window the review proposes for reassessing inpatient antibiotics: confirm the diagnosis and results, then stop, de-escalate or switch from intravenous to oral therapy
- ≥70%of human antibiotic use to be Access agents by 2030: the global aim the WHO AWaRe framework is used to monitor
- 20prescriptions a month may be adequate for rapid local feedback in primary care, though generally too small for precise comparison between facilities
Abstract
Antimicrobial resistance increases treatment failure, complications, mortality, and avoidable expenditure, particularly where diagnostic and stewardship capacity is limited. This narrative review examines how antimicrobial stewardship can translate policy into safer prescribing across primary, emergency, inpatient, and transition-of-care settings. Structured searches of biomedical databases, international repositories, and relevant national guidance informed a thematic synthesis of implementation barriers, core interventions, syndrome-based pathways, antibiotic classification, measurement, and discharge stewardship. Recurring barriers include unclear accountability, workforce and diagnostic constraints, weak information systems, prescribing norms, patient expectations, market pressures, and fragmented care. The review proposes a scalable package centred on syndrome-based prescribing, documentation of indication and duration, reassessment within 48–72 hours, intravenous-to-oral switching, selection aligned with the World Health Organization Access, Watch, and Reserve (AWaRe) framework, discharge review, and a small balanced set of antibiotic-use and safety indicators. These practical pathways and tools require local adaptation to epidemiology, resistance patterns, diagnostic capacity, regulation, and resources. Antimicrobial stewardship should be implemented as a patient-safety and quality-improvement strategy, with prospective evaluation of feasibility, clinical outcomes, and unintended consequences.
Introduction
Antimicrobial resistance (AMR) is a major global health threat that is eroding progress in infectious-disease control and making some infections increasingly difficult to treat. In 2019, bacterial AMR was associated with an estimated 4.95 million deaths, including 1.27 million deaths attributable to resistance. Resistant infections can prolong hospital stays, increase complications and costs, and threaten procedures such as caesarean delivery, chemotherapy, and organ transplantation that depend on effective antimicrobial prophylaxis and treatment.1,2
Recent global surveillance reports continue to document substantial and uneven AMR burdens, particularly in resource-constrained settings and among older adults, with increasing resistance in several Gram-negative pathogens.3 Scenario-based analyses have projected that, without effective action, AMR could cause up to 10 million deaths annually by 2050 and cumulative economic losses of up to USD 100 trillion; these figures are projections rather than observed outcomes.4 Clinically, resistance increases the risk of ineffective initial therapy, prolonged illness, complications, and mortality, while a limited antibiotic pipeline especially for resistant Gram-negative pathogens, reinforces the need for prevention, access, and stewardship.3–5
The World Health Organization Global Action Plan frames AMR as a systemic, multisectoral challenge requiring a coordinated One Health response across human, animal, agricultural, and environmental sectors. Its five strategic objectives address awareness, surveillance and research, infection prevention and control, optimized antimicrobial use, and sustainable investment.6 India’s first National Action Plan on AMR covered 2017–2021 and emphasized governance, surveillance, infection prevention and control, optimized antimicrobial use, research, and intersectoral coordination; implementation was uneven because of fragmented systems and resource constraints.7,8
In LICs including India, where infectious disease- burden and poor access to antibiotics remain high, extending stewardship beyond tertiary hospitals to primary care is essential, as primary care contributes the largest share of antibiotic prescribing.9,10 Despite clear policy direction, implementation across hospital and outpatient settings remains uneven, highlighting the need for pragmatic, workflow compatible tools and a reframing of AMS as a core component of clinical excellence and patient safety rather than administrative compliance.11,12
This narrative review examines antimicrobial stewardship as a foundation for clinical excellence and patient safety by translating global and national policy into practical strategies for primary care and hospital settings. It identifies recurring barriers including diagnostic limitations, prescribing behaviours, data gaps, incentives, and discontinuities across care and distinguishes those that are broadly transferable from those requiring local adaptation. It then presents pragmatic flowcharts, syndromic pathways, and indicator- and checklist-based tools for high-volume, resource-constrained environments. Although examples are drawn partly from India, the implementation principles are intended for adaptation across diverse health systems, particularly in low- and middle-income countries.
Literature search and narrative synthesis
This narrative review was informed by structured searches of PubMed/MEDLINE, World Health Organization and United Nations repositories, and relevant national government and professional guidance. Searches covered literature published up to 2025 and combined terms relating to antimicrobial stewardship, antimicrobial resistance, AWaRe, primary care, hospitals, intensive care, syndromic pathways, audit and feedback, prescribing defaults, transitions of care, antibiotic consumption, defined daily doses, days of therapy, and point prevalence surveys. Reference lists of key guidelines and reviews were also screened. Priority was given to contemporary guidelines, systematic reviews, consensus statements, implementation studies, and evidence from low- and middle-income countries; seminal earlier publications were retained when they remained foundational.
Sources were selected for their relevance to practical stewardship across the care continuum, recency, methodological robustness, and applicability to resource-constrained settings. Evidence was synthesized thematically around implementation barriers, core interventions, syndromic decision pathways, AWaRe-aligned prescribing, measurement, and transitions of care. Where evidence or recommendations differed, the manuscript reports the variation and interprets it in relation to clinical setting, population, diagnostic capacity, and implementation feasibility rather than resolving disagreement through quantitative pooling. As this was a narrative rather than systematic review, duplicate independent screening, formal risk-of-bias assessment, and meta-analysis were not undertaken.
Interpretation of recommendations considered the underlying evidence source. Recommendations supported by comparative clinical studies or established guidelines are presented as evidence-informed; practical workflow tools, sequencing choices, and proposed indicator sets that rely mainly on expert consensus or implementation experience are identified as pragmatic options whose effectiveness should be evaluated locally.
This review has limitations. The narrative design may have introduced selection and interpretation bias, and the absence of formal risk-of-bias assessment limits certainty about the comparative effectiveness of specific interventions. Evidence is heterogeneous across settings, and several proposed tools and indicator sets are based on guideline recommendations, expert consensus, or implementation experience rather than controlled evaluations. The India-focused policy and regulatory examples may not transfer directly to other jurisdictions. Accordingly, the pathways and indicators should be adapted to local epidemiology, resistance patterns, formularies, diagnostic capacity, financing, regulation, and scope-of-practice arrangements, with prospective evaluation of clinical and safety outcomes.
Challenges to Antimicrobial Stewardship Implementation Across Care Levels
Antimicrobial stewardship faces interlinked system, workforce, diagnostic, information, and behavioural barriers across tertiary hospitals and primary care. Hospitals must manage high-acuity illness, large caseloads, complex prescribing decisions, and multiple handovers, whereas primary care is characterized by diagnostic uncertainty, time pressure, patient expectations, limited follow-up, and substantial responsibility for antibiotic prescribing.13 These constraints are often amplified in resource-limited settings by limited microbiology capacity, delayed specimen transport, shortages of trained clinicians and pharmacists, variable access to electronic health records, and little or no dedicated stewardship support. The barriers described below therefore interact across care levels and should be addressed through context-specific, phased implementation.
Governance and accountability gaps weaken stewardship when responsibility for antibiotic outcomes is unclear, programmes are treated as optional, or policies lack authority and implementation support. Cross-country analyses show substantial variation in the alignment, financing, accountability, and implementation of national AMR plans, with many low- and middle-income countries facing greater resource and system constraints.14,15
Human resource- and workflow constraints with limited infectious disease expertise-, microbiology support, and stewardship pharmacists, combined with high clinical workload- restrict prospective review, feedback, and clinician engagement.16
Diagnostic and information system limitations including delayed or poor quality- microbiology, inconsistent specimen collection, limited access to rapid diagnostics, and weak antibiograms, reduce confidence in deescalation. Lack of electronic prescribing or usable -antibiotic use data further obscures stewardship impact.17
Prescribing culture and clinical uncertainty drive unnecessary antibiotic use. Fear of missing sepsis, medicolegal concerns, escalation norms, and hierarchical structures hinder feedback. Fragmented documentation and diffuse team ownership reinforce inertia once antibiotics are started.18
Patient, community, and market pressures amplify inappropriate antimicrobial use, particularly in primary care. Expectations for antibiotics, self-medication, non-prescription access, incomplete courses, and switching between agents interact with supply-chain constraints, stock-outs, formulary gaps, concerns about medicine quality, pharmaceutical promotion, and sales incentives. These influences can shift prescribing towards unnecessary or broader-spectrum treatment for self-limiting presentations such as viral upper respiratory tract infections, uncomplicated acute watery diarrhoea, and undifferentiated fever.19–23
Fragmentation across care transitions: Fragmented care transitions further weaken stewardship, as antibiotics started in EDs or outpatient settings are often continued without review, and discharge prescriptions may lack stop dates or follow-up plans.
Regulatory oversight can influence antimicrobial use through prescription-only controls, market authorization, enforcement, and quality assurance. In India, concerns include persistent availability of irrational fixed-dose combinations, variable enforcement of Schedule H1, and access to antibiotics through informal, retail, and online channels.24–28 Comparable regulatory mechanisms differ across countries; therefore, the relevant stewardship response should be adapted to national legislation, dispensing systems, market incentives, and medicine-quality surveillance. Substandard or falsified antimicrobial products may further worsen clinical outcomes and resistance selection.23,24
Limited context-specific clinical evidence: In India and many low-income and resource-constrained settings, high-quality evidence from randomized controlled trials and prospective cohort studies remains limited for several antimicrobial stewardship prescribing strategies. This evidence gap can reduce clinician confidence in adapting recommendations derived from other health systems and make entrenched prescribing practices more difficult to challenge. Locally generated implementation and outcome studies are therefore needed to assess effectiveness, safety, feasibility, and transferability across diverse care settings.
Core Antimicrobial Stewardship Interventions in Tertiary and Primary Care
Hospital-based AMS programs reduce inappropriate antimicrobial use, resistance, and costs without compromising outcomes. Core components include:
Multidisciplinary AMS team: Effective stewardship relies on collaboration between infectiousdisease clinicians, microbiologists, and pharmacists, who jointly support diagnosis, culture interpretation, and appropriate antimicrobial- selection and monitoring.29 This shared model distributes responsibility and strengthens accountability for antibiotic outcomes.
Antimicrobial stewardship teams function effectively when integrated with governance structures such as the Pharmacy & Therapeutics Committee, Patient Safety Committee, and IPC Committee, enabling alignment of policies, formulary decisions, and surveillance activities across the hospital.10,14
Evidence based antibiotic policies and formularies: Locally adapted, regularly updated policies and formularies provide a standard reference for empiric and definitive therapy, align prescribing with resistance patterns, and reduce unwarranted variation. Leadership endorsement ensures they support safe, consistent practice.14
Prospective audit with feedback: Structured reassessment at defined intervals allows confirmation of diagnosis, incorporation of microbiology results, and timely deescalation, discontinuation, or IV-to-oral- switch. This process counteracts “inertia” where antibiotics continue unnecessarily.30,31
Local antibiograms: Unit or -hospitalspecific- resistance data guide rational empiric choices, build confidence in using narrower agents, and link individual decisions to institutional resistance trends.32
Pre-authorization: Use of high-risk or newly introduced antimicrobials is regulated through AMS approval based on defined criteria. These controls ensure justified use across ICUs, wards, and EDs.10,14 For example, requiring AMS approval before initiating carbapenems (e.g., meropenem, imipenem) for suspected sepsis when no MDR risk factors are present; linezolid or daptomycin for suspected MRSA infections when a βlactam could still be effective; limiting use of ceftazidime–avibactam or cefiderocol only to confirmed CRE/MDR Gram negative infections, with AMS team signoff.
Formulary restriction: Pharmacy and therapeutics committees should review antimicrobial combinations and duplicative agents for evidence of clinical benefit, safety, quality, and local regulatory approval rather than relying on market availability alone. The WHO AWaRe framework can support spectrum-aligned restriction, promote Access first-line choices, and protect Watch and Reserve agents across the facility (Table 3).10,14,33
Workflow integration: AMS is most effective when embedded into routine clinical processes, using practical, high-yield actions that reduce unnecessary antibiotic use without adding workload.
Table 1 translates the core components above into a one-page launch guide for tertiary and primary care, distinguishing service-level interventions from repeatable bedside and outpatient actions.
Table 1. Core AMS interventions and corresponding AMS actions (Clinical perspective) Tertiary care (Wards / ICU) and Primary Care
| TERTIARY CARE (WARDS/ICU) |
|---|
| AMS interventions |
| Prospective audit & feedback with 48–72 h antibiotic “time-outs” to reassess diagnosis, cultures, de-escalation, IV-to-oral switch, and stop dates. |
| Formulary & restriction policies for last-line agents (e.g., carbapenems, colistin, linezolid), tied to short approval forms and rapid post-prescription review. |
| Syndrome-based treatment and duration guidelines |
| Local/unit antibiograms to guide empiric choices and reduce unnecessary broad-spectrum coverage. |
| Surgical prophylaxis governance: correct agent; single dose/≤24 h; monthly feedback by procedure. |
| AMS action (Specific day-to-day clinical behaviours that operationalize stewardship - the “how” at the bedside or in the OPD |
| Minimum documentation dataset on all orders: indication/site, planned duration, day count, and review/stop date. |
| 48–72 h time-out + de-escalation expectation in ICU and two high-use wards. |
| Surgical prophylaxis ≤24 h for top procedures. |
| Restricted-antibiotic workflow (carbapenems/colistin/linezolid/vancomycin) with rapid review. |
| Culture-before-first-dose bundle in ED/ICU (specimen quality, contamination monitoring). |
| Syndrome-based duration cards/order sets (CAP, UTI, SSTI, IAI)3. |
| Discharge antibiotic pause/checklist to count total days and write stop dates. |
| PRIMARY CARE (OPD) |
| Default “no-antibiotic” pathways for viral URTI, Day-1 undifferentiated fever, and acute watery diarrhea (with safety-netting and scheduled review). |
| Criteria-based prescribing for sore throat (CENTOR), otitis media (watchful waiting unless severe/<2 years), and sinusitis (persistent >10 days, severe, double-worsening). |
| Short, guideline-concordant courses with written stop dates (e.g., cystitis 3–5 d; CAP 5 d when improving). |
| Simple audit and feedback (mini-audits of 20 prescriptions/month; indicators for URTI/diarrhea antibiotic rates; documentation of durations) |
Note: Interventions are structured stewardship tools the service sets up; actions are repeatable clinical behaviours that deliver them at the bedside/OPD. Use this integrated table as a one-page launch guide and scale up later.
In hospitals, these actions are embedded at four decision points-initiation, 48–72-hour review, peri-operative care, and discharge-with clear ownership and lightweight measurement supporting de-escalation and duration control.34
In primary care, implementation can begin with no-antibiotic defaults, criteria-based prescribing, short courses with stop dates, and brief monthly audits.35
Minimum feasible package: Smaller hospitals may begin with a concise antibiotic policy, documentation of indication and planned duration or review date, 48–72-hour reassessment in selected wards or for restricted agents, audit of surgical prophylaxis, and periodic sample-based review. Primary care facilities may prioritize no-antibiotic pathways for likely self-limiting illness, criteria-based prescribing, short-course guidance where supported by local recommendations, safety-net advice, and review of a small prescription sample. More resource-intensive activities such as unit-specific antibiograms, continuous prospective audit, advanced dashboards, and specialist pre-authorization, can be added as capacity develops. The package should be adapted to local case mix, staffing, diagnostic access, prescribing authority, and referral pathways.
Syndromic Approach: Core Syndromes and Management
A syndromic approach operationalizes stewardship through presentation-based pathways that define when to withhold, initiate, review, and stop antibiotics across primary care, emergency departments, and hospital wards (Table 2).36 These pathways require adaptation to age, comorbidity, pregnancy, immune status, illness severity, local epidemiology, diagnostic access, resistance patterns, and nationally endorsed treatment guidance; they should support rather than replace individual clinical assessment.
Table 2. How to apply Syndromic Approach (primary care and wards/ICU)
| ANTIBIOTIC-SMART SYNDROMIC PATHWAY: PRIMARY CARE AND WARDS/ICU | |
|---|---|
| Right patient • right drug • right duration • documented stop/review date | |
| 1. Screen for danger signs | SpO2 <94%/respiratory distress; systolic blood pressure <90 mmHg/shock; altered sensorium/seizure; severe dehydration or inability to drink; suspected meningitis, severe pneumonia, or sepsis; pregnancy or immunocompromise with systemic illness. Stabilize, document vital signs/focus, and refer urgently. |
| 2. If stable: default no-antibiotic care | Viral upper respiratory infection: symptomatic care. Undifferentiated day-1 fever: no routine antibiotic; consider local malaria/dengue patterns and reassess in 24–48 hours. Acute watery diarrhoea: oral rehydration; zinc in children. Give written safety-net advice. |
| 3. Start only when criteria are met | Sore throat: high CENTOR score; about 10 days per local protocol. Otitis media: severe illness, age <2 years, or no improvement; 5–7 days, longer if severe/young. Bacterial sinusitis: >10 days, severe onset, or double worsening; 5–7 days. Stable community-acquired pneumonia: treat per local guideline; usually 5 days if improving; refer if hypoxic/frail/severe. |
| 4. Other common syndromes | Dysentery/invasive diarrhoea: 3–5 days per local aetiology; reassess at 48 hours. Uncomplicated cystitis: 3–5 days; do not treat asymptomatic bacteriuria except in pregnancy/urological procedures. Febrile urinary tract infection/pyelonephritis: 5–7 days; refer if pregnancy, obstruction, acute kidney injury, sepsis, oral intolerance, or poor response. Skin/soft-tissue infection: drain abscess; antibiotics for cellulitis/systemic signs, about 5 days. Dental infection: source control; antibiotics only for swelling, fever, trismus, spread, or immunocompromise, 3–5 days. |
| 5. Document every antibiotic | Diagnosis/site; drug and dose; duration; stop date; review plan. Count previous doses. Use default durations only with good clinical response and no complications. |
| 6. Inpatient review | Send cultures before the first dose when feasible. At 48–72 hours, confirm diagnosis/results and stop, de-escalate, or switch intravenous to oral therapy. Prefer Access agents where appropriate; restrict Watch/Reserve agents to defined indications with active review. |
| Compact indicator set | Indication/duration/stop-date documentation; cultures before first dose when indicated; 48–72-hour review; de-escalation or intravenous-to-oral switch; antibiotic prescribing per 100 outpatient visits; 7–14-day re-consultation/referral after a no-antibiotic decision. |
Table 3. WHO AWaRe categories with setting-specific clinical examples and medicines
| Category and use | Illustrative medicines | Primary care/outpatient examples | Hospital/ICU examples | Stewardship signal |
|---|---|---|---|---|
| ACCESS Preferred first- or second-line agents; narrower spectrum and lower resistance pressure. | Amoxicillin, ampicillin, amoxicillin-clavulanate, cefalexin, doxycycline, nitrofurantoin, metronidazole, benzylpenicillin | Amoxicillin for uncomplicated community-acquired pneumonia or pharyngitis; nitrofurantoin for uncomplicated cystitis; doxycycline for selected respiratory infections. | Ampicillin/sulbactam or cefazolin for susceptible infection; cefalexin oral step-down for skin/soft-tissue infection; metronidazole for anaerobic infection. | Promote and protect: increasing Access share and Access:Watch ratio indicate first-line alignment. |
| WATCH Broader-spectrum agents with higher resistance risk; use selectively with active review. | Ceftriaxone, ceftazidime, cefepime, ciprofloxacin, levofloxacin, azithromycin, clarithromycin, piperacillin-tazobactam, vancomycin | Azithromycin only for defined community-acquired pneumonia/atypical indications; avoid routine fluoroquinolones for uncomplicated cystitis or diarrhoea. | Ceftriaxone for severe pneumonia or sepsis; piperacillin-tazobactam for suspected severe polymicrobial infection; reassess at 48–72 hours. | Monitor: rising Watch share or a falling Access:Watch ratio signals broad-spectrum drift. |
| RESERVE Last-resort agents for confirmed or strongly suspected multidrug-resistant infection; strict oversight. | Colistin, ceftazidime-avibactam, imipenem-relebactam, cefiderocol, linezolid, daptomycin, tigecycline | Rarely appropriate; specialist referral and microbiological guidance generally required. | Colistin or newer β-lactam/β-lactamase inhibitor agents for resistant Gram-negative infection; linezolid/daptomycin for resistant Gram-positive infection. | Protect: track justified Reserve days of therapy per 1,000 patient-days. |
~AWaRe categories reflect how antibiotics should be used and monitored to limit resistance -not drug “strength.” Lists are illustrative and should be adapted to local formularies and resistance patterns.
Standardized thresholds reduce unwarranted variation while preserving clinical judgment for complex or high-risk cases; time-bound inpatient reassessment counters escalation bias and prompts de-escalation or discontinuation.37
Using the same pathways across settings also improves documentation and continuity at high-risk transitions, particularly emergency admission and discharge.22–24 These pathways also support a small set of syndrome- and AWaRe-aligned indicators for audit and feedback.38–40
Antimicrobial Stewardship Flowchart – Tertiary Care Hospital
The tertiary-care flowchart applies the four hospital decision points described above within urgent inpatient pathways, linking prompt treatment of severe infection with structured reassessment and de-escalation.3
Figures 1 and 2 show risk stratification for the emergency department and ICU/IPD, respectively, with documentation and follow-up requirements matched to clinical severity.
AWaRe (Access, Watch, Reserve) categorisation
The WHO AWaRe framework classifies antibiotics by spectrum and resistance pressure to guide both prescribing and monitoring; it is not a measure of “strength.” It is updated periodically and used for consumption monitoring, target setting, and policy evaluation, including the global aim that ≥70% of human antibiotic use be Access agents by 2030.34,40–43
Table 3 translates AWaRe categories into setting-specific examples: Access agents are preferred first-line options, Watch agents require selective use and active review, and Reserve agents require exceptional justification and stewardship oversight.
For monitoring, the most useful summary measures are Access share, the Access: Watch ratio, and justified Reserve days of therapy per 1,000 patient-days (Table 4).
Table 4. Antimicrobial Stewardship Indicators for All Settings & Tertiary-Care Hospitals
| Core indicator and setting | Measure and desired signal | Data source and purpose |
|---|---|---|
| STRUCTURE AND GOVERNANCE | ||
| Functional stewardship programme Hospital/intensive care | Named multidisciplinary team, current policy/formulary, protected time, and actions tracked | Governance records: accountability and sustained implementation |
| Diagnostic and resistance support Hospital/intensive care | Microbiology access, turnaround time monitored, and current local antibiogram | Laboratory reports: targeted empiric therapy and de-escalation |
| CORE PRESCRIBING AND REVIEW | ||
| Indication and duration documented All settings | Percentage of orders with diagnosis/site and duration, review, or stop date; higher is better | Prescription/electronic records: prevents unintended prolonged therapy |
| Cultures before first dose when indicated Emergency/hospital/intensive care | Percentage of eligible cases sampled before therapy; higher is better | Laboratory/prescription records: supports narrowing or cessation |
| Guideline-concordant initial therapy All settings | Percentage concordant with local guideline/antibiogram; higher is better | Prescription audit: reduces unnecessary broad-spectrum exposure |
| 48–72-hour review and action Hospital/intensive care | Percentage reviewed; stop, de-escalation, or intravenous-to-oral switch documented | Stewardship/ward audit: converts results and response into action |
| Surgical prophylaxis beyond 24 hours Hospital/operating theatre | Percentage exceeding 24 hours; lower is better | Theatre/pharmacy records: limits avoidable postoperative exposure |
| Priority outpatient syndrome prescribing Primary care/outpatient | Antibiotic percentage for viral upper respiratory infection or watery diarrhoea; lower with safety checks | Prescription review: tracks no-antibiotic pathways |
| USE, SPECTRUM, OUTCOMES, AND FEEDBACK | ||
| Access share and Access:Watch ratio Hospital/intensive care | Access percentage and ratio rising; Watch use falling | Pharmacy/stewardship dashboard: monitors AWaRe alignment |
| Restricted/Reserve antibiotic use Hospital/intensive care | Days of therapy per 1,000 patient-days with justification; unjustified use falling | Pharmacy/review logs: protects last-resort agents |
| Clinical safety outcome All settings | Treatment failure, referral, mortality, or 30-day readmission monitored with use reductions | Clinical records: balances stewardship with timely effective care |
| Resistance and antibiotic-related harm Hospital/intensive care | Selected multidrug-resistant organism and Clostridioides difficile rates; downward trend desired | Microbiology/infection-control data: tracks ecological and patient harm |
| Audit-feedback action loop All settings | Periodic dashboard shared; named actions, owners, and follow-up recorded | Stewardship/quality records: turns measurement into improvement |
Mini-Audit & Feedback
A monthly review of a purposive or randomly selected sample of prescriptions can provide a feasible entry-level audit for primary care. The sampling frame, eligible encounters, syndrome definitions, denominator, reviewer, and criteria for appropriateness should be specified in advance. A sample of 20 prescriptions may be adequate for rapid local feedback but is generally too small for precise comparison between facilities or for inference about population-level prescribing.44
Brief, non-punitive feedback makes prescribing patterns visible, supports sustained behaviour change, and builds readiness for more advanced stewardship activities.
Measuring Antibiotic Consumption and Use
Antibiotic-use measurement complements clinical audit by quantifying exposure and enabling comparison across time, units, and surveillance systems.
At hospital and population levels, antimicrobial consumption is commonly measured using defined daily doses (DDD), the World Health Organization’s assumed average maintenance dose per day for a medicine used for its main indication in adults. Hospital consumption is often expressed as DDD per 1,000 patient-days, whereas community consumption is commonly expressed as DDD per 1,000 inhabitants per day. Defined daily doses supports trend analysis and benchmarking but is a technical consumption unit rather than a prescribed or recommended dose; it does not reliably represent paediatric use, renal dose adjustment, individual dosing intensity, or actual patient-level exposure.45–47
Days of therapy (DOT) measure the number of calendar days on which a patient receives a specified antimicrobial, irrespective of dose; each antimicrobial contributes separately on a given day. Days of therapy is commonly expressed per 1,000 patient-days and is more responsive than DDD to duration-focused interventions such as discontinuation, de-escalation, and intravenous-to-oral switching. However, it requires reliable patient-level medication administration or prescribing data and may not be feasible in all settings.34,46
Point prevalence surveys (PPS) provide a cross-sectional snapshot of antimicrobial prescribing on a specified day or period, including indication, agent, route, review or stop date, and selected quality indicators. Repeated PPS using a consistent method can track changes in prescribing quality, although PPS is less suitable than longitudinal consumption data for measuring total antimicrobial volume. Its principal value is to identify improvement priorities, assess guideline concordance, and compare prescribing patterns when denominators and case mix are clearly reported.48
Sakai et al found that using the automated Antimicrobial and Patient Background Surveillance System led to a significant short-term reduction in both carbapenem and antipseudomonal antibiotic use.49
Used together, DDD and DOT quantify consumption and exposure, while PPS assesses prescribing quality; AWaRe adds a spectrum-based policy lens.
Cross-cutting: Indicators, Checklists for Monitoring & Feedback
In resource-constrained settings, monitoring should begin with three to five indicators that are actionable, clearly defined, and obtainable from existing records (Table 4). A practical core set may include documentation of indication; planned duration, review date, or stop date; completion of a 48–72-hour review where applicable; antibiotic prescribing for one priority primary-care syndrome; and Access share or use of one selected broad-spectrum agent. Each indicator should specify its numerator, denominator, eligible population, data source, review interval, and balancing safety measure. Re-consultation, referral, mortality, treatment failure, or readmission should accompany reduction targets, while DDD, DOT, resistance, expenditure, and unit-level indicators can be introduced as data quality and analytic capacity improve.
Transitions of care & Discharge
Discharge is the final stewardship checkpoint. The checklist in Table 5 verifies diagnosis, culture follow-up, narrowest effective agent, total inpatient-plus-outpatient duration, stop date, monitoring, and responsibility for pending results.
Table 5. Antibiotic Discharge Checklist (Tick-box, OPD-friendly)
| Patient: __________ UHID: ________ Date: ___/___/____ Unit/Doctor: __________ Diagnosis/site: ______________________________ | |
|---|---|
| 1. Need and results | ☐ Indication and red flags documented; stop if infection is unlikely ☐ Cultures: ☐ not indicated ☐ blood ☐ urine ☐ respiratory ☐ wound/other ______ ☐ Result: ☐ final/reviewed ☐ pending—expected ___/___; reviewer/contact __________ ☐ Regimen aligned with result or no-growth plan documented |
| 2. Agent and route | ☐ Narrowest effective agent; no duplicate coverage ☐ oral step-down appropriate ☐ Allergy/reaction: ☐ none known ☐ __________________ ☐ important interactions checked |
| 3. Dose and patient factors | SCr/eGFR: ______ date ___/___ Weight: ____ kg ☐ Renal/dialysis adjustment ☐ hepatic factors considered ☐ monitoring arranged |
| 4. Duration—mandatory | Inpatient days: ____ Total duration: ____ days Stop date: ___/___/____ ☐ Review trigger documented for deterioration, persistent fever, or new symptoms |
| 5. Source and devices | ☐ Source control completed/planned: __________________ ☐ Catheter/line and wound-care plan documented where relevant |
| 6. Patient safety | ☐ Written dose/timing instructions ☐ adverse effects and urgent-return signs explained ☐ Missed-dose advice; no self-extension or sharing of leftovers |
| 7. Follow-up and summary | Follow-up: ___/___/____ Clinic/contact: __________________ ☐ Pending-result action assigned ☐ return precautions documented ☐ Summary states indication, cultures, final regimen, start date, and stop date |
| Final discharge antibiotic plan Drug 1: ______ Dose: ____ Route: ____ Frequency: ____ Start: ___/___ Stop: ___/___ Drug 2, if required: ______ Dose: ____ Route: ____ Frequency: ____ Start: ___/___ Stop: ___/___ | |
Conclusion
The way forward is to assign clear ownership for the workflows and measures presented in Tables 1–5 and embed a small set of high-value actions into routine care. Nurses can support early recognition, specimen quality, documentation, counselling, and adherence to review or stop dates; pharmacists can optimize agent, dose, route, interactions, and duration; and diagnostic stewardship can enable confident narrowing or cessation of therapy.50–52 Programmes should begin with feasible, locally agreed guidance, prescribing prompts, stop dates, focused review of high-risk antibiotics, and periodic prescription sampling, then add referral laboratory networks, regional antibiograms, electronic alerts, dashboards, continuous audit, and specialist review as capacity develops. Sustainability requires visible leadership endorsement, named accountability, protected time, integration with patient-safety, pharmacy, infection-prevention, and accreditation systems, regular multidisciplinary training, accessible local guidance, supportive feedback, and periodic review of balanced process, antibiotic-use, clinical, and safety indicators.
Effective antimicrobial stewardship depends less on the number of interventions adopted than on reliably delivering indication and duration documentation, syndrome-specific criteria, defined reassessment, AWaRe-aligned selection, and an explicit discharge plan. Public education should complement clinical systems by aligning expectations, reducing demand for unnecessary antibiotics, and promoting adherence and safe self-care.19 A phased, locally adapted approach that pairs antibiotic-use measures with patient-safety outcomes can translate antimicrobial-resistance policy into safer prescribing while preserving timely access to effective treatment.
References
- Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi:10.1016/S0140-6736(21)02724-0.
- World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) report 2025. Geneva: World Health Organization; 2025.
- George NA, Pan D, Silva L, Baggaley RF, Irizar P, Divall P, et al. The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patients. eClinicalMedicine. 2025;87:103384. doi:10.1016/j.eclinm.2025.103384.
- Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial resistance: a growing serious threat for global public health. Healthcare (Basel). 2023;11(13):1946. doi:10.3390/healthcare11131946.
- Balasegaram M, Outterson K, Røttingen JA. The time to address the antibiotic pipeline and access crisis is now. Lancet. 2024; 404(10461):1385–1387. doi:10.1016/S0140-6736(24)01940-8.
- Ministry of Health and Family Welfare, Government of India. National Action Plan on Antimicrobial Resistance (NAPAMR) 2017–2021. New Delhi; 2017. https://www.who.int/publications/m/item/india-national-action-plan-on-antimicrobial-resistance-%28nap-amr%29-2017-2021.
- Ministry of Health and Family Welfare, Government of India. National Action Plan on Antimicrobial Resistance (NAPAMR) 2.0 (2025–2029). New Delhi; 2025. https://www.ncdc.mohfw.gov.in/wp-content/uploads/2025/11/National-Action-Plan-on-Antimicrobial-Resistance-NAP-AMR-2.0.pdf
- Centers for Disease Control and Prevention. Core Elements of Outpatient Antibiotic Stewardship. Atlanta: CDC; 2016. https://www.cdc.gov/antibiotic-use/hcp/core-elements/index.html
- Sharma A, Thakur N, Thakur A, Chauhan A, Babrah H. The Challenge of Antimicrobial Resistance in the Indian Healthcare System. Cureus. 2023 Jul 21;15(7):e42231. doi: 10.7759/cureus.42231.
- Bohan, J.G., Hunt, L. & Madaras-Kelly, K. Antimicrobial Stewardship Guidelines: Syndrome-Specific Strategies. Curr Treat Options Infect Dis. 2017; 9, 68–79. https://doi.org/10.1007/s40506-017-0107-y https://link.springer.com/content/pdf/10.1007/s40506-017-0107-y.pdf
- Thoonsen AC, van Schoten SM, Merten H, van Beusekom I, Schoonmade LJ, Delnoij DMJ, et al. Stimulating implementation of clinical practice guidelines in hospital care from a central guideline organization perspective: a systematic review. Health Policy. 2024;148:105135. doi:10.1016/j.healthpol.2024.105135.
- Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the IDSA and SHEA. Clin Infect Dis. 2016;62(10):e51–e77.
- Raka L, Kurti A. Addressing barriers in antimicrobial stewardship: a guide from research to implementation. J Glob Antimicrob Resist. 2024;39(Suppl):26. doi:10.1016/j.jgar.2024.10.082.
- Patel J, Saeedi Moghaddam S, Ranganathan S, Vezeau N, O'Neill E, Harant A, et al. Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories. Lancet Infect Dis. 2026;26(1):55–66. doi:10.1016/S1473-3099(25)00406-2.
- Munkholm L, Rubin O. The global governance of antimicrobial resistance: a cross-country study of alignment between the global action plan and national action plans. Glob Health. 2020;16(1):109. doi:10.1186/s12992-020-00639-3.
- Shamas N, Stokle E, Ashiru-Oredope D, Wesangula E. Challenges of implementing antimicrobial stewardship tools in low- to middle-income countries (LMICs). Infect Prev Pract. 2023;5(4):100315. doi:10.1016/j.infpip.2023.100315.
- El-Kareh R, Hasan O, Schiff GD. Use of health information technology to reduce diagnostic errors. BMJ Qual Saf. 2013;22(Suppl 2):ii40–ii51. doi:10.1136/bmjqs-2013-001884.
- Acampora M, Paleologo M, Graffigna G, Barello S. Uncovering influential factors in human antibiotic prescribing: a meta-synthesis study informed by the Theoretical Domains Framework. J Hosp Infect. 2024;144:28–55. doi:10.1016/j.jhin.2023.11.017.
- Sharma S, Gupta R, Bablani V, Bahl A. Nurturing Tomorrow's Antibiotic Stewards: An Innovative School Campaign to Combat Antimicrobial Resistance in Delhi. Indian Journal of Public Health 68(1): pp 133-136, Jan–Mar 2024. DOI: 10.4103/ijph.ijph_305_23
- Sangeeta Sharma, CB Tripathi, Mridula Kapil Bhargava, Nishtha Dang, Aditi Sharma, Sandeep Bhalla. School-Based Education on Infection Prevention, Antimicrobial Use: A Strategic Entry Point for Raising Antimicrobial Resistance Awareness. Preventive Medicine: Research & Reviews (Accepted for Publication Feb 2026).
- Cohn J, Mendelson M, Kanj SS, Shafiq N, Boszczowski I, Laxminarayan R. Accelerating antibiotic access and stewardship: a new model to safeguard public health. Lancet Infect Dis. 2024;24(9):e584–e590. doi:10.1016/S1473-3099(24)00070-7.
- Modgil V, Sahay S, Mukherjee A, Banta R, Joshi N, Surial R, et al. Integrating procurement, prescription, and resistance data to strengthen antimicrobial stewardship: insights from a public health institution in India. Front Microbiol. 2025;16:1673019. doi:10.3389/fmicb.2025.1673019.
- Kamere N, Rutter V, Munkombwe D, Aywak D, Muro E, Kaminyoghe F, et al. Supply chain factors and antimicrobial stewardship. Bull World Health Organ. 2023;101:403–411. doi:10.2471/BLT.22.288650.
- Porter G, Kotwani A, Bhullar L, Joshi J. Overthecounter sales of antibiotics for human use in India: The challenges and opportunities for regulation. Med Law Int. 2021;21(2):147173.
- Kotwani A, Joshi J, Lamkang AS. Overthecounter sale of antibiotics in India: A qualitative study of providers’ perspectives across two states. Antibiotics. 2021;10(9):1123. doi:10.3390/antibiotics10091123.
- Joshi AV, Albhar S, Nilesh K, Ashwini N, Ganesh D. Review on Schedule H and H1. Int J Creative Res Thoughts (IJCRT). 2023;[paper ID IJCRT2301332].
- Mathew P, Thomas SA, Chandy SJ. The role of Schedule H1 and Red Line campaign in improving antibiotic use in India. J Family Med Prim Care. 2022;11(6):26562661. doi:10.4103/jfmpc.jfmpc_1811_21.
- Farooqui HH, Selvaraj S, Mehta A, Mathur MR. The impact of stringent prescriptiononly antimicrobial sale regulation (Schedule H1) in India: an interrupted time series analysis, 2008–18. JACAntimicrob Resist. 2020;2(3):dlaa076. doi:10.1093/jacamr/dlaa076.
- Alves J, Schouten J, Thursky K, Paz RN, Rello J, Lye DC, et al. Establishing core competencies for antimicrobial stewardship teams: a consensus development using the modified Delphi technique - an European Society of Clinical Microbiology and Infectious Diseases Study Group for Antimicrobial Stewardship position paper. Clin Microbiol Infect. 2025;31(8):1313–1320. doi:10.1016/j.cmi.2025.04.035.
- Thakkar P, Singhal T, Shah S, Bhavsar R, Ladi S, John RE, et al. The implementation and outcome of a 2-year prospective audit and feedback based antimicrobial stewardship program at a private tertiary care hospital. Indian J Med Microbiol. 2021;39(4):425–428. doi:10.1016/j.ijmmb.2021.09.005.
- Morrill HJ, Caffrey AR, Gaitanis MM, LaPlante KL. Impact of a prospective audit and feedback antimicrobial stewardship program at a Veterans Affairs Medical Center: a six-point assessment. PLoS One. 2016;11(3):e0150795. doi:10.1371/journal.pone.0150795.
- Klinker KP, Hidayat LK, DeRyke CA, DePestel DD, Motyl M, Bauer KA. Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms. Ther Adv Infect Dis. 2021;8:1–9. doi:10.1177/20499361211011373.
- World Health Organization. AWaRe classification of antibiotics for evaluation and monitoring of use, 2023. Geneva: World Health Organization; 2023 Jul 26. [cited 2026 Jan 14]. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.04
- Mohapatra S, Safiq N, Panda PK. An integrated antimicrobial stewardship approach in tertiary care hospitals in developing countries using a multidomain framework (“PRESCRIBES” checkpoint): a call for action. Int J Infect Dis. 2026;164:108388. doi:10.1016/j.ijid.2026.108388.
- Subedi S, Harris PNA, Hall L, Paterson DL. Practical considerations for implementation of syndromic panel and diagnostic stewardship in the era of syndromic panel testing. Clin Microbiol Infect. 2025 Nov;31(11):1822-1827. doi: 10.1016/j.cmi.2025.06.013.
- Dumkow LE, Worden LJ, Rao SN. Syndromic diagnostic testing: a new way to approach patient care in the treatment of infectious diseases. J Antimicrob Chemother. 2021;76(Suppl 3):iii4–iii11. doi:10.1093/jac/dkab245.
- Klinker K, Bauer KA, DeRyke CA, Hidayat LK. Empiric antibiotic susceptibility using a traditional vs. syndromic antibiogram - implications for antimicrobial stewardship programs. Open Forum Infect Dis. 2020;7(Suppl 1):S65–6. doi:10.1093/ofid/ofaa439.148.
- Sinha I, Kanth K, Krishnamoorthy Y, Gopichandran V. Access-Watch ratio based on access, watch, and reserve classification of antibiotics in public health facilities of Tamil Nadu. Indian J Public Health. 2022 Jul-Sep;66(3):352-354. doi: 10.4103/ijph.ijph_274_22.
- Timbrook TT, Campbell C, Bailey P. Antimicrobial stewardship in long-term care facilities: evidence-based interventions, implementation tools, and impact metrics. Antimicrob Steward Healthc Epidemiol. 2025;6(1):e6. doi:10.1017/ash.2025.10255.
- Mudenda S, Daka V, Matafwali SK. World Health Organization AWaRe framework for antibiotic stewardship: Where are we now and where do we need to go? An expert viewpoint. Antimicrob Steward Healthc Epidemiol. 2023 Apr 26;3(1):e84. doi: 10.1017/ash.2023.164.
- United Nations General Assembly. Political declaration of the high-level meeting on antimicrobial resistance. New York: United Nations; 2024. [cited 2026 Jan 15]. Available from: https://www.un.org/pga/wp-content/uploads/sites/108/2024/09/FINAL-Text-AMR-to-PGA.pdf
- Klein EY, Impalli I, Poleon S, Denoel P, Cipriano M, Van Boeckel TP, et al. Global trends in antibiotic consumption during 2016–2023 and future projections through 2030. Proc Natl Acad Sci U S A. 2024;121(49):e2411919121. doi:10.1073/pnas.2411919121.
- World Health Organization. The WHO AWaRe (Access, Watch, Reserve) antibiotic book. Geneva: World Health Organization; 2022.
- Cassim J, Essack SY, Chetty S. An audit of antibiotic prescriptions: an antimicrobial stewardship pre-implementation study at a tertiary care public hospital. JAC Antimicrob Resist. 2025;7(1):dlae219. doi:10.1093/jacamr/dlae219.
- Kanda N, Ohbe H, Jo T, Matsui H, Fushimi K, Hatakeyama S, et al. Trends in inpatient antimicrobial consumption using days of therapy and days of antibiotic spectrum coverage: a nationwide claims database study in Japan. J Infect Chemother. 2024;30(3):228–235. doi:10.1016/j.jiac.2023.10.012.
- Jabeen N, Ullah W, Khalid J, Samad Z. Estimating antibiotic consumption in a tertiary care hospital in Islamabad using the World Health Organization defined daily dose methodology. Antimicrob Resist Infect Control. 2023;12(1):132. doi:10.1186/s13756-023-01311-2.
- Namita Vilas Nasare, Ankit Bhardwaj, Vineeta Bablani, Renu Gupta, Suman Kushwaha, Sangeeta Sharma. Antimicrobial Utilization Study in a Neurology Setting. JIMA; 121, Issue-4, April 2023, pp 41-44.
- World Health Organization. WHO methodology for point prevalence survey on antibiotic use in hospitals. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.
- Sakai M, Sakai T, Watariguchi T, Kawabata A, Shirai M, Kakimoto M, et al. Effectiveness of an antimicrobial stewardship program using an automated antimicrobial surveillance system based on indication for antimicrobial administration. J Pharm Health Care Sci. 2025. https://doi.org/10.1186/s40780-025-00528-0
- Gupta R, Sharma S, Bablani V, Manocha S, Srinivasan M. Empowering nurses for effective diagnostic stewardship: An initiative to address anti-microbial resistance. Nurse Educ Pract. 2025 Jan; 82:104223. doi: 10.1016/j.nepr.2024.104223. Epub 2024 Dec 5. PMID: 39671750.
- Sharma S, Juneja S, Ramesh B, Venkatesh L, Varghese V, Tripathi CB. Enhancing nursing competencies in antimicrobial and diagnostic stewardship through continuing education. Med Res Arch. 2026;14(1). doi:10.18103/mra.v14i1.7209.
- Sharma S, Gupta R, Warrier AR, Rai S, Manchanda V, Gupta E, et al. Strengthening antimicrobial stewardship via diagnostic stewardship education. Med Res Arch. 2026;14(1). doi:10.18103/mra.v14i1.7185.
Article information
Authors
- Sangeeta SharmaProfessor, Department of Neuropsychopharmacology, Institute of Human Behaviour and Allied Sciences, Delhi, IndiaCorresponding author · [email protected]
- Anup R WarrierSenior Consultant - Infectious Disease Specialist, Group Chief of Medical Services, BMH Care Hospital Limited, Ernakulam, Kerala, India
- Tarun SinghMedication Safety Officer, and Chief Pharmacist, MM Institute of Medical Sciences & Research, Mullana, Ambala, Haryana, India
- Aashima DabasProfessor, Department of Pediatrics, Maulana Azad Medical College & LN Hospital, Delhi, India
- Shivani JunejaSenior Consultant, Clinical Pharmacology, Healing Super Specialty Hospital, Chandigarh, Union Territory Punjab & Haryana
- Sarbjeet KhuranaAssociate Professor, Department of Epidemiology, Institute of Human Behaviour and Allied Sciences, Delhi, India
How to cite
Sharma, S., Warrier, A. R., et al., 2026. From Policy to Practice: Implementing Antimicrobial Stewardship Across the Care Continuum. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.v14i10.7886
Record
- Journal
- Medical Research Archives
- Issue
- Vol 14 No 10 (2026)
- Section
- Review Articles
- Published
- 27 October 2026
- ISSN
- 2375-1924
- Downloads
- 103
Copyright and licence
Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.